Dialysis industry news

Stories from the dialysis comunity across the globe.



A Gold Rush In Medical Design, Inspired Partly By iPads - Co.Design PDF Print

About 1 in 3 Americans suffer from some level of hypertension. Some of them can control their blood pressure problems through medication, but for those who can’t, renal denervation is a promising new technique that’s getting an incredible amount of buzz in the health (and venture capital) community.

The procedure is relatively simple: A catheter enters the renal artery and burns out a bit of nerve tissue around the artery walls, thwarting overactive signals coming from the kidneys that throw the body into blood pressure hyperdrive. One early clinical trial has shown that, over three years, 100% patients with severe hypertension were apparently cured by the technique. And for most, results took a mere six months of treatment.

Yet despite all this interest and potential, there’s just one company that makes a renal denervation device (which is approved for Europe and undergoing FDA testing now). Their name is Ardian, a they were recently acquired for about $1 billion.

Subsequently, the field has been labeled a “gold rush” with anywhere from 16-40 companies on the market, all trying to grab their seat at the renal denervation table. Vessix Vascular is just one of those companies, but they believed they had the technology to compete. So they teamed up with Karten Design to flesh out their device as a marketable product that could stand out from the pack to attract doctors, investors, and even consumers who might find themselves in the patient chair.

“We learned that the Vessix system had a key advantage over Ardian’s—speed,” Karten Design’s principal Stuart Karten (and Co.Design guest blogger) tells us. “Vessix’s proprietary catheter could perform renal denervation in just 30 seconds per artery, compared to Ardian’s 20-30 minutes per artery. Speed became one of the advantages we sought to highlight through design.”

So in a field of medical devices that’s dominated by forty shades of beige boxes, Karten designed the Vessix to visually compete with the latest in consumer electronics, mixing matte bead-blasted aluminum and shiny anodized housing to pop and shimmer in smooth, strong curves, like Callaway’s latest driver lying on the backseat of a freshly-waxed European sports car. (Well, relatively speaking.)

“It looks fast,” writes Karten. “The Vessix generator doesn’t have a single flat surface. ‘You know, this thing will never have to sit on a table…’ our Design Director Eric Olson mused in an early design review. The realization that this pole-mounted device would never have to sit on a table freed us to create the sweeping, parabolic form without back or bottom. It actually appears to be levitating on the pole like a high-tech spaceship—an effect that adds to its intrigue.”

Sex appeal was one selling point, but simply to pass FDA inspection, the Vessix V2 would need to be easy to use. Big, clear iconography was key. And whereas it may look like it has a multitouch display just urging a deadly typo in latex gloves, the device is actually operated by a single button. “They’re notified that the catheter is in place, prompted to push the button to deliver treatment, and then given an on-screen summary,” writes Karten. The entire process is a trip through just four screens.

Time will tell if Vessix is able to break into the market before renal denervation becomes a household term like “dialysis” or “chemo.” But it’s fascinating that, even in a field traditionally dominated by scientific advancement, creating an elegant solution has become synonymous with creating a smart one.

...

 
NephroPlus to set up 40 kidney care clinics in North India over next 3 years - Economic Times PDF Print

HYDERABAD: City-based NephroPlus, a kidney care clinics chain, will set up 40 of its proposed 100 dialysis centres in North India over the next three years, a senior official said today.

"From the present seven kidney care clinics, we are expanding our operations, and will set up 100 kidney care and dialysis clinics across the country. Of these, 40 will come up in North India," NephroPlus Founder and CEO Vikram Vuppala told reporters here.

NephroPlus, in the meanwhile, announced that Dr Brian J G Pereira is joining its board as a director.

The company, which received first round of funding from venture capital firm Bessemer Venture Partners last year, was now looking forward for right partnerships towards its plan of setting up the 100 centres, he said.

Vuppala declined to give investment details.

NephroPlus will have standalone clinics as well as in tie-up with leading hospitals, he added.

...

 
FDA Approves Novartis' Afinitor for Treating Renal Angiomyolipoma Associated ... - Genetic Engineering News PDF Print

FDA granted accelerated approval to NovartisAfinitor® (everolimus) tablets for the treatment of adult patients with renal angiomyolipomas and tuberous sclerosis (TSC) complex who don’t need immediate surgery. The firm says the mTor inhibitor treatment is the first to be cleared for use in this patient population.

TSC is a genetic disorder that can cause noncancerous tumors to form in vital organs, and up to 80% of patients will develop angiomylopiomas that can lead to severe kidney damage and require surgery. Skin lesions in addition occur in over 90% of TSC patients.

U.S. approval of everolimus for the TSC and angiomyolipoma indication was based on data from the placebo-controlled Phase III Exist-2 study, which demonstrated a 42% angiomyolipoma response rate among patients treated with Afinitor compared with 0% for placebo-treated patients. Afinitor therapy also significantly prolonged time to angiomyelipoma progression. There was in addition a 26% skin lesion response rate (a 50% or more improvement) among the 97% of trial patients who presented with skin lesions.

Afinitor has previously been approved in the U.S. and other markets for the treatment of adult patients with advanced renal cell carcinoma, progressive neuroendocrine tumors of pancreatic origin, and for treating adult adn pediatric patients with subependymal giant cell astrocytoma (SEGA) associated with TSC who aren’t suitable for surgical intervention. Everolimus is in addition marketed in the U.S. and other countries under the trade names Zortress and Certican for use in the prevention of organ rejection in adult kidney and heart transplant patients.

The drug is undergoing Phase III development in combination with exemestane as a treatment for postmenopausal women with ER+Her2- advanced breast cancer.

...

 
Home-based dialysis more popular in developing countries - News-Medical.net PDF Print

Researchers at Lawson Health Research Institute have discovered that developing countries have faster growing rates of use of home-based dialysis (called peritoneal dialysis) for kidney failure than the developed world. Despite home-based dialysis' reduced cost and better outcomes, developed countries (including Canada) are using this form of therapy less.

The study by Dr. Arsh Jain, Lawson researcher and Nephrologist at London Health Sciences Centre, was published in the Journal of American Society Nephrology (JASN) last month. Peritoneal dialysis represents only 11 per cent of dialysis patients worldwide.

While the overall use of peritoneal dialysis for kidney failure is climbing world wide, rates are climbing quickly in developing countries. According to Dr. Jain, peritoneal dialysis is more cost effective than hospital-based dialysis (called hemodialysis). Dr. Jain and his colleagues analyzed records from 1997 to 2008 in 130 countries in order to come up with the conclusion that developed countries are using peritoneal dialysis less.

The study found that 59 per cent of peritoneal patients were treated in developing countries as opposed to 41 per cent in developed countries. Throughout the 12 years of the study, peritoneal dialysis patients in developing countries increased by 24.9 patients per million populations and in developed countries only 21.8 per million populations. Despite this increase the overall proportion of all dialysis patients that are treated with peritoneal dialysis in developed countries has in fact declined by 5.3 per cent, while developing countries have had no change.

"Our findings may impact future business and research innovations," said Dr. Jain. "It may be the developing world and not the developed world that drives future medical innovations in peritoneal dialysis." These results also serve as a call to action for developed countries to increase the use of this effective therapy.

Source: Lawson Health Research Institute

...

 
Dialysis providers Fresenius, DaVita target Metro East - St. Louis Business Journal PDF Print

Two of the nation’s largest dialysis providers are investing more than $6 million to open new centers in the Metro East.

Fresenius Medical Care, a Waltham, Mass.-based company that operates nearly 2,900 dialysis clinics worldwide, plans to spend $3.9 million to relocate its existing BMA Southwestern Illinois dialysis center in East Alton to a new location in Alton. Fresenius competitor DaVita Inc.    DaVita Inc. Latest from The Business Journals Briefcase Plus: Boulder environmental firm lands M Interior Dept. contractWarren Buffett says his prostate cancer is not life-threateningDaVita turns to interim CFO is seeking approval to open a $2.4 million dialysis clinic in Red Bud, Ill.

The demand for dialysis centers across the region and nationwide is on the rise. More than 26 million patients currently suffer from chronic kidney ...

Health care, Technology
bizWatch

See all your followed company news on your personalized dashboard.

To access the full benefits of bizWatch and receive a weekly email with aggregated news on all the companies you are following, please provide your email address below.

You must have a bizjournals account to follow a company.
Please Log In or Register.

Already a subscriber? Sign in to link your subscription

...

 
<< Start < Prev 761 762 763 764 765 766 767 768 769 770 Next > End >>

Page 762 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.